stockrow
Saturday 7 November 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
3.92
0.16
+4.26%
Follow MNKD
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 7 | 7 | 3 | 3 | 4 | 3 | 6 | — | — |
P/E ratio |
255.41 | 62.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61 |
Altman Z-Score |
(3.63) | (7.24) | (7.55) | (13.46) | (12.02) | (38.65) | (45.12) | (39.91) | (51.29) | (31.65) |
P/S ratio |
4.97 | 6.18 | 5.26 | 13.43 | 14.44 | 10.69 | 4.00 | 5.48 | 23.61 | 1.66 |
P/FCF ratio |
126.60 | 53.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(11.89) | (22.33) | (18.67) | (33.74) | (29.67) | (94.80) | (108.31) | (94.01) | (121.75) | (80.69) |
P/Operating CF |
(217.76) | 77.92 | 48.28 | (563.74) | (88.22) | 2,964.64 | (49.40) | 6.11 | (9.25) | (22.81) |
Beneish M-Score |
0.65 | (1.84) | (2.54) | (1.06) | (0.10) | (3.84) | 11.01 | (5.22) | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
5.79 | 5.98 | 5.65 | 15.50 | 16.28 | 11.55 | 5.09 | 6.59 | 32.84 | 2.38 |
EV/EBITDA |
38.89 | 20.92 | 73.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.83 |
EV/Operating CF |
110.64 | 40.16 | 32.98 | (19.16) | (19.90) | (26.75) | (3.63) | (4.87) | (5.96) | (5.33) |
EV/FCF |
147.54 | 52.02 | (134.71) | (17.52) | (16.78) | (26.00) | (3.53) | (4.84) | (5.96) | (5.26) |
Quick Ratio |
1.23 | 2.55 | 2.98 | 2.79 | 4.32 | 0.97 | 0.82 | 1.01 | 0.58 | 0.58 |
Current Ratio |
1.70 | 3.28 | 3.59 | 3.49 | 4.54 | 1.08 | 0.93 | 1.09 | 0.65 | 0.84 |
Net Debt/EBITDA |
5.32 | (0.83) | 3.77 | (3.71) | (3.30) | (1.25) | (1.57) | (0.42) | (1.04) | 1.76 |
Debt/Assets |
56.52% | 32.99% | 74.25% | 127.87% | 106.76% | 113.03% | 126.86% | 95.15% | 185.42% | 138.70% |
Debt/Equity |
(8.78) | (1.65) | (1.43) | (1.51) | (1.64) | (0.68) | (0.62) | (0.59) | (0.73) | (0.81) |
Asset Turnover |
0.59 | 0.66 | 0.52 | 0.32 | 0.35 | 0.64 | 0.63 | 0.29 | 0.12 | 1.50 |
Operating CF/Net income |
3.11 | 1.54 | (2.86) | 0.92 | 0.76 | 0.49 | 1.70 | 0.43 | 0.55 | (0.62) |
Capex/Depreciation |
(0.35) | (1.07) | (6.41) | (0.90) | (2.31) | (0.24) | (2.64) | (0.08) | 0.01 | (0.27) |
Interest Coverage |
1.02 | 1.91 | 0.34 | (2.59) | (2.84) | (5.06) | (4.09) | (8.11) | (8.15) | 3.64 |
| (9.03%) | (16.98%) | 4.81% | 38.01% | 41.53% | 30.86% | 28.39% | 44.62% | 58.91% | (47.07%) | |
| 0.99% | 6.35% | (3.10%) | (28.36%) | (37.66%) | (56.58%) | (51.53%) | (90.47%) | (122.45%) | 107.65% | |
ROIC |
10.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
2.89% | 10.15% | (3.38%) | (41.09%) | (38.95%) | (180.92%) | (236.82%) | (269.98%) | 3,392.11% | 874.85% |
Average Days of Receivables |
40.13 | 15.09 | 27.34 | 61.47 | 22.93 | 23.63 | 20.34 | 52.63 | 86.67 | 64.45 |
Research and Development Expense of Revenue |
19.01% | 16.07% | 15.72% | 19.77% | 16.32% | 29.90% | 10.95% | 31.36% | 120.20% | 8.54% |
Selling, General and Administrative Expense of Revenue |
41.30% | 33.04% | 47.40% | 91.68% | 102.62% | 90.63% | 118.45% | 286.14% | 638.22% | 26.85% |
Intangible Assets out of Total Assets |
0.09 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.93% | 7.48% | 8.87% | 13.48% | 16.17% | 9.99% | 9.84% | 24.61% | 41.27% | 2.94% |
Graham Net Nets |
(0.32) | (0.12) | (0.33) | (0.23) | (0.29) | (0.30) | (0.89) | (1.32) | (0.87) | (0.73) |
Graham Number |
0.00 | 0.00 | 1.00 | 2.73 | 2.46 | 2.14 | 2.43 | 4.15 | 7.17 | 0.00 |
Earnings Yield |
0.39% | 1.60% | (1.22%) | (6.53%) | (7.32%) | (7.99%) | (20.93%) | (59.43%) | (41.73%) | 38.29% |
Free Cash Flow Yield |
0.79% | 1.86% | (0.80%) | (6.59%) | (6.72%) | (4.15%) | (36.09%) | (24.85%) | (23.35%) | (27.23%) |
Revenue per Share |
1.14 | 1.04 | 0.75 | 0.39 | 0.30 | 0.29 | 0.32 | 0.19 | 0.11 | 1.90 |
Operating CF per Share |
0.06 | 0.15 | 0.13 | (0.31) | (0.25) | (0.13) | (0.45) | (0.26) | (0.62) | (0.85) |
Capex per Share |
(0.01) | (0.04) | (0.16) | (0.03) | (0.05) | 0.00 | (0.01) | 0.00 | 0.00 | (0.01) |
Free Cash Flow per Share |
0.04 | 0.12 | (0.03) | (0.34) | (0.29) | (0.13) | (0.47) | (0.26) | (0.62) | (0.86) |
Cash per Share |
0.56 | 0.72 | 1.11 | 0.66 | 0.82 | 0.30 | 0.26 | 0.50 | 0.46 | 0.25 |
Shareholders Equity per Share |
(0.17) | (0.29) | (0.92) | (0.97) | (0.84) | (0.81) | (0.97) | (1.21) | (2.06) | (1.99) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.17) | (0.29) | (0.92) | (0.97) | (0.84) | (0.81) | (0.97) | (1.21) | (2.06) | (1.99) |
Free Cash Flow |
13.69 | 32.82 | (8.35) | (88.27) | (73.17) | (28.93) | (91.05) | (37.96) | (64.75) | (79.22) |
Working Capital |
120.55 | 186.47 | 269.27 | 167.60 | 171.14 | 5.77 | (4.86) | 6.61 | (30.38) | (14.56) |
Capital Expenditures |
(4.57) | (9.69) | (42.44) | (7.59) | (11.47) | (0.80) | (2.56) | (0.23) | 0.02 | (1.13) |
Net Current Asset Value |
(551.62) | (204.35) | (347.97) | (310.92) | (311.02) | (209.55) | (223.49) | (200.93) | (242.09) | (213.17) |
EV/EBIT |
52.05 | 23.52 | 129.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.19 |
Capex to Sales |
0.01 | 0.03 | 0.21 | 0.08 | 0.15 | 0.01 | 0.04 | 0.01 | 0.00 | 0.01 |
Price to Operating Income |
44.66 | 24.31 | 120.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.32 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.16 | 0.11 | 0.08 | 0.19 | 0.14 | 0.13 | 0.04 | 0.11 | 0.13 | 0.14 |
Cash ROIC |
2.41% | 13.21% | (2.08%) | (29.63%) | (21.67%) | (304.39%) | 424.92% | 4,162.83% | 677.70% | 649.16% |
Accounts Receivable Turnover |
13.91 | 21.38 | 12.55 | 9.26 | 16.85 | 16.85 | 16.74 | 8.19 | 0.70 | 11.32 |
Accounts Payable Turnover |
11.12 | 9.36 | 6.08 | 6.39 | 6.20 | 4.75 | 5.50 | 3.31 | 3.36 | 5.31 |
Inventory Turnover |
2.78 | 2.71 | 2.50 | 3.98 | 6.41 | 5.40 | 7.22 | 6.55 | 6.91 | 8.35 |
Average Days of Payables |
37.49 | 32.36 | 55.71 | 70.16 | 65.34 | 82.68 | 62.47 | 95.92 | 147.97 | 23.78 |
Days of Inventory on Hand |
146.54 | 132.87 | 165.98 | 138.21 | 67.18 | 73.66 | 54.20 | 64.14 | 56.29 | 16.99 |
Average Receivables |
25.09 | 13.35 | 15.85 | 10.77 | 4.48 | 3.87 | 3.77 | 3.40 | 16.82 | 15.44 |
Average Payables |
7.91 | 8.19 | 10.32 | 9.00 | 6.27 | 5.19 | 5.08 | 6.18 | 5.12 | 9.43 |
Average Inventory |
31.60 | 28.22 | 25.16 | 14.46 | 6.06 | 4.56 | 3.88 | 3.13 | 2.49 | 6.00 |
Average Assets |
593.01 | 434.52 | 385.24 | 308.22 | 214.88 | 101.17 | 100.72 | 96.14 | 95.82 | 116.74 |
Average Common Equity |
(64.92) | (162.49) | (248.35) | (229.94) | (194.88) | (185.47) | (182.80) | (194.91) | (199.16) | (266.96) |
Columns are period end dates · fundamentals updated 5 Nov 2026